Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.37 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | CCR6 | P51684 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4260736 | 1.00 | F2R (0.42) | F2RMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL4255400 | 0.87 | PYGL (0.43) | MEN1KMT2AHPGDSORT1AGTR1 | |
| SCHEMBL4255393 | 0.87 | PYGL (0.43) | MEN1KMT2AHPGDSORT1AGTR1 | |
| SCHEMBL4255228 | 0.85 | SORT1 (0.42) | MEN1KMT2ASORT1AGTR1GRM5 | |
| SCHEMBL4255220 | 0.85 | SORT1 (0.42) | MEN1KMT2ASORT1AGTR1GRM5 | |
| SCHEMBL4255193 | 0.84 | NFE2L2 (0.47) | F2RMEN1KMT2AALDH1A1AGTR1 | |
| SCHEMBL4255200 | 0.84 | NFE2L2 (0.47) | F2RMEN1KMT2AALDH1A1AGTR1 | |
| SCHEMBL27726688 | 0.81 | TGFBR1 (0.41) | F2RMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL4256700 | 0.81 | TGFBR1 (0.41) | F2RMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL5426634 | 0.78 | KMT2A (0.52) | F2RMEN1KMT2AALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1904471-B1 | HETEROARYLETHENYL DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2009-10-21 | — | — | EP | claimed |
| US-7208506-B2 | Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | claimed |
| US-20070010564-A1 | Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2007-01-11 | — | — | US | claimed |
| EP-1904471-B1 | HETEROARYLETHENYL DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2009-10-21 | — | — | EP | disclosed |
| US-7208506-B2 | Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20070010564-A1 | Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010564-A1 | Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents | CYP3A43, CYP1A1, CYP3A5 | F2R 258/4885MEN1 394/4885KMT2A 2988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.